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Quantifying the Release of Biomarkers of Myocardial
Necrosis from Cardiac Myocytes and Intact
Myocardium
Jack Marjot,1† Thomas E. Kaier,1† Eva D. Martin,1 Shiney S. Reji,2 O’Neal Copeland,2 Mohammed Iqbal,3
Bob Goodson,4 Sarah Hamren,4 Sian E. Harding,2 and Michael S. Marber1*
BACKGROUND: Myocardial infarction is diagnosed when
biomarkers of cardiac necrosis exceed the 99th centile,
although guidelines advocate even lower concentrations
for early rule-out.We examined howmanymyocytes and
how much myocardium these concentrations represent.
We also examined if dietary troponin can confound the
rule-out algorithm.
METHODS: Individual rat cardiac myocytes, rat myocar-
dium, ovine myocardium, or human myocardium were
spiked into 400-L aliquots of human serum. Blood was
drawn from a volunteer after ingestion of ovine myocar-
dium. High-sensitivity assays were used to measure car-
diac troponin T (cTnT; Roche, Elecsys), cTnI (Abbott,
Architect), and cardiac myosin-binding protein C
(cMyC; EMD Millipore, Erenna®).
RESULTS: The cMyC assay could only detect the human
protein. For each rat cardiac myocyte added to 400L of
human serum, cTnT and cTnI increased by 19.0 ng/L
(95% CI, 16.8–21.2) and 18.9 ng/L (95% CI, 14.7–
23.1), respectively. Under identical conditions cTnT,
cTnI, and cMyC increased by 3.9 ng/L (95% CI, 3.6–
4.3), 4.3 ng/L (95% CI, 3.8–4.7), and 41.0 ng/L (95%
CI, 38.0–44.0) per g of human myocardium. There
was no detectable change in cTnI or cTnT concentration
after ingestion of sufficient ovinemyocardium to increase
cTnT and cTnI to approximately 1  108 times their
lower limits of quantification.
CONCLUSIONS: Based on pragmatic assumptions regard-
ing cTn and cMyC release efficiency, circulating species,
and volume of distribution, 99th centile concentrations
may be exceeded by necrosis of 40 mg of myocardium.
This volume is much too small to detect by noninvasive
imaging.
© 2017 American Association for Clinical Chemistry
Cardiac troponin (cTn),5 released in the setting of myo-
cardial necrosis, is engrained in the universal definition of
myocardial infarction (1 ). This definition incorporates a
diagnostic threshold concentration at the 99th centile for
the general population. More recent guidelines suggest
rule-in and rule-out cutoffs widely spaced around the
99th centile and utilize small changes in concentration
between first and second blood draw (the  values) to
identify acute myocardial injury (2 ). The guideline pub-
lished by the European Society of Cardiology lists  val-
ues derived from observational studies (3–5 ) and advo-
cates changes in the concentration of high-sensitivity
cardiac troponin T (hs-cTnT; Roche) 3 ng/L and hs-
cTnI (Abbott) 2 ng/L, to identify patients for early
discharge (rule-out). The low magnitude of the absolute
and  concentrations used to rule out myocardial infarc-
tion (MI) have stimulated debate (6–9 ). To our knowl-
edge, no previous study has established how many myo-
cytes, or how much myocardium, needs to undergo
necrosis to exceed the 99th centile, rule out cutoff, or rule
out  values. We set out to address this question by sim-
ulating myocardial injury using defined numbers of car-




Adult rat ventricular myocytes were isolated from the
hearts of male Wistar rats weighing approximately 200–
250 g (B&K Universal Ltd.) by a collagenase-based
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enzymatic method as described in (10 ). In brief, hearts
were excised from terminally anesthetized and heparin-
ized (60 mg/kg sodium pentobarbitone and 100 U so-
dium heparin, intraperitoneally) rats. Excised hearts were
immediately cannulated and initially perfused for 5 min
with HEPES-Tyrode solution containing the following
(mmol/L): 130 NaCl, 4.5 MgCl2, 0.4 NaH2PO4, 0.75
CaCl2, 4.2 HEPES, 20 taurine, 10 creatine, and 10
glucose. Hearts were then consecutively perfused with
Ca2-free HEPES-Tyrode solution containing 100
mol/L EGTA (10 min) and HEPES-Tyrode solution
containing 100 mol/L CaCl2 and 1 g/L type II collage-
nase (Worthington Biochemical Corp., 8 min). All solu-
tions were gassed with 100% O2 and maintained at
37 °C. Hearts were then removed from the perfusion
apparatus, the ventricles were cut into small pieces, and
agitated for a further 7 min at 37 °C. Isolated myocytes
were separated from the undigested ventricular tissue by
filtering through 200-mnylon gauze, and the cells were
allowed to settle by gravity (8 min). The supernatant was
removed and replaced with HEPES-Tyrode solution
containing 1% BSA and 500 mol/L CaCl2. Myocytes
were again allowed to settle, the supernatant was re-
moved, and the cells were finally pooled and resuspended
in 30 mL of HEPES-Tyrode solution containing 1
mmol/L CaCl2. The pooled isolated myocytes were pel-
leted by brief centrifugation at 50g and washed at room
temperature with modified M199 culture medium (In-
vitrogen) containing 2 mmol/L Creatine, 2 mmol/L car-
nitine and 5 mmol/L taurine supplemented with 100
IU/mL penicillin/streptomycin. Following further cen-
trifugation at 50g, myocytes were finally resuspended in
modified M199 medium. Myocytes were then plated
onto 6-well culture plates precoated with laminin and
allowed to attach for 90 min in an incubator (37 °C, 5%
CO2). Unattached cells were removed after preplating for
2 h and the culture medium was replaced with fresh
modified M199 medium, and the cells were maintained
overnight. Cultured rat cardiomyocytes were subse-
quently resuspended in Tyrode solution. Trypan blue
staining revealed a viability of 45%. Cells were allowed to
settle in Tyrode’s solution. The solution was subse-
quently removed and replaced with 10 mL Tris (20
mmol, pH 7.5), then centrifuged at 94g for 3 min. The
wash supernatant was discarded, and the cell pellet resus-
pended in fresh Tris solution. Cell count was calculated
using an automated cell counter (Bio-Rad TC20™). The
results of the automated cell counterwere calibrated toman-
ual cell counts attained by visual inspection with a hemocy-
tometer. The 10 mL of resuspended pellet was then ultra-
sonicated (610-s bursts on ice, with 10-s intervals on ice).
Dilutions of this solution were then spiked into 400 L of
banked human serum.
Experiments with cultured rat myocytes were re-
peated using 4 different human serum samples to ac-
count for donor-dependent interaction between human
serum and rat protein. Experiments were repeated once
for 2 of the serum donors using a different stock solution
of cultured myocytes, so as to account for variation be-
tween culture preparations. Cells were spiked into serum
in increments of 10 cells, ranging from 1 cell to 90 or 100
cells (limited by the availability of cells and serum). These
repeat experiments resulted in a total of 62 samples for
assessment of linear correlation.
HUMAN MYOCARDIUM
Human myocardium was obtained from an explanted
failing heart under Ethical Approval from the Royal Bro-
mpton and Harefield Trust BRU Biobank, which com-
plies with the Helsinki declaration of 1975. The tissue
was transported in cardioplegia, and frozen at 80 °C.
Frozen myocardium was weighed (the exact weight was
recorded), and the tissue was crushed in a percussion
mortar for 10 s. Buffer solution [50 mL Tris, pH 7.5,
with 1 tablet protease inhibitor (complete EDTA-free,
Roche)] was added to the pulverized tissue (1 mL of
buffer per 100 mg of tissue). The subsequent solution
was ultrasonicated on ice (6  10-s bursts on ice, with
10-s intervals on ice). Following ultrasonication, the so-
lution was centrifuged at 21.130g for 30 mins at 4 °C.
The supernatant was frozen in liquid nitrogen and then
stored at 80 °C. Dilutions of this solution were then
spiked into 400 L of banked human serum.
Experiments using human myocardium were lim-
ited in number by availability of myocardial tissue, and
were repeated using serum obtained from 3 different do-
nors. Myocardium was spiked into serum at a concentra-
tion of 1 g, 10 g, and increments of 10 g up to 100
g. With addition of blank controls (serum  buffer),
this resulted in a total of 36 samples for assessment of
linear correlation.
DIETARY TROPONIN CONSUMPTION
Ovine left ventricular myocardium was boiled in water
for 3 h and then mechanically homogenized using a glass
handheld homogenizer. Buffer solution [50 mL Tris, pH
7.5 with 1 tablet protease inhibitor (complete EDTA-
free, Roche)], was added to the homogenized tissue (1
mL of buffer per 100 mg of tissue). The subsequent so-
lution was ultrasonicated on ice (6  10-s bursts on ice,
with 10-s intervals on ice). Following ultrasonication, the
solution was centrifuged at 21.130g for 30 mins at 4 °C.
The supernatant was frozen in liquid nitrogen and then
stored at 80 °C. Dilutions of this solution were then
spiked into 400 L of banked human serum to generate
a calibration curve. A healthy human volunteer with a
baseline serum troponin (T and I) below the limit of
detection had a 200-g dietary load of ovine left ventricu-
lar myocardium boiled for 3 h. Serial venipuncture was
2 Clinical Chemistry 63:5 (2017)
performed from an antecubital fossa vein at 15, 60, 120,
180, 240, 1320, and 1640 min after ingestion.
BIOMARKER MEASUREMENT
The concentrations of cTnI and cTnT were measured
using contemporary high-sensitivity assays [Abbott Ar-
chitect, limit of detection (LoD) 1.9 ng/L; and Roche
Elecsys, LoD 5 ng/L, respectively], (11–13). Cardiac
myosin-binding protein C (cMyC) was measured by
EMD Millipore on the Erenna® platform using propri-
etary reagents as recently described (LoD of 0.4 ng/L)
(14 ). A triplicate standard curve was run and used to
interpolate the data.
For all samples, the biomarker concentration in the
blank control was subtracted from the total biomarker con-
centration of each sample, to control for variation in tro-
ponin concentrations within the human serum or the back-
ground signal generated by buffer alone. Samples of Tris
buffer added to banked human serum (serving as controls
for each experiment) returned cTnT values between LoD
and 6.98 ng/L, cTnI values between LoD and 5.00 ng/L,
and cMyC values between 11.37 and 26.78 ng/L.
Likely compatibility of the high sensitivity troponin
assays with rat cTn was assessed by basic local alignment
search tool (BLAST) comparison of the amino acid
sequence of rat troponin and the detection/capture
epitopes for the high-sensitivity assay antibodies (see Fig.
S1 in the Data Supplement that accompanies the online
version of this article at http://www.clinchem.org/content/
vol63/issue5). The amino acid sequence for these epi-
topes was largely conserved between the human and rat
proteins. This molecular suggestion of compatibility was
borne out in the strong signal detected by the assays in rat
and ovine cardiac tissues.
STATISTICAL ANALYSIS
Linear regression analysis was used to assess correlation,
and standardized residuals greater than 3 SDs were
excluded as outliers (n 1). Statistical analysis was con-
ducted using SPSS version 22 (IBMCorp.) and R version
3.3.0 (GUI 1.68, The R Foundation for Statistical
Computing).
Results
The cMyC assay did not detect rat cMyC since the cap-
ture and detection antibodies are directed at human-
specific sequences [see Fig. 3 in (15 )]. There is a strong
linear correlation between rat cardiomyocyte number
and cTn concentration (cTnI;R2 0.58, P0.001, n
61; cTnT; R2  0.83, P 0.001, n  62; Fig. 1). We
were able to detect, in 400 L of serum, a cTn increase
resulting from a single cardiomyocyte. The slope coeffi-
cients for both cTnI and cTnT were similar [cTnI
slope  18.9 ng.L1/cell (95% CI, 14.7–23.1); cTnT
slope  19 ng.L1/cell (95% CI, 16.8–21.2) and the
lines of regression did not deviate significantly from the
origin [cTnI y-intercept  44.6 ng.L1 (95% CI,
128.8 to 39.5) and cTnT y-intercept  24.4 ng.L1
(95% CI, 18.9 to 67.7]. One outlier was identified
during linear regression with a standardized residual3
SDs. No other outliers were identified, and in the context
of strong linear correlations either side of this point, this
outlier was assumed to represent a user-operated pi-
petting error.
In experiments using human myocardium, both the
cTns and cMyC were strongly linearly correlated with
mass of myocardium [cTnI R2  0.92, P 0.001, n 
36, slope  4.3 ng.L1/g (95% CI, 3.8–4.7), y-inter-
cept  4.4 ng.L1 (95% CI, 20.1 to 28.8)], [cTnT
R2  0.93, P 0.001, n  36, slope  3.9 ng.L1/g
(95%CI, 3.6–4.3), y-intercept 19.0 ng.L1 (95%CI,
1.6 to 39.5)], [cMyC R20.96, P  0.001, n  36,
slope  41.0 ng.L1/g (95% CI, 38.0–44.0), y-inter-
cept 91.1 ng.L1 (95% CI,79.3 to 261.4)] (Fig. 2).
Cooked ovine myocardium had a much greater tro-
ponin content than human myocardium, and a robust
linear correlation was established between mass of myo-
cardium and troponin release [hs-cTnI R2  0.992,
P0.0001, n 12, slope 4928 ng.L1/g (95% CI,
4616–5241)], [hs-cTnT R20.998, P  0.0001, n 
12, slope  11512 ng.L1/g (95% CI, 11225–
11798)]. Despite this extreme sensitivity, at all measured
time points following an oral load of similarly processed
ovine myocardium, the concentration of both cTnI and
cTnT remained below the LoD for their respective assays
when measured in human peripheral venous circulation
(Fig. 3).
Discussion
This study documents the extreme sensitivity of the high-
sensitivity cTn assays, which are capable of detecting re-
lease from a single cardiomyocyte in a 400-L blood
sample. All investigated biomarkers correlate strongly
with the mass of human myocardium. The observation
that each microgram of human myocardium releases less
cTn than a single cardiomyocyte most likely results from
the heterogeneous cellular makeup of the human heart
samples and the difficulty in efficiently liberating sarco-
meric protein.
Despite the extreme sensitivity of cTn assays, we
were unable to detect exogenous cTn in the peripheral
blood stream after an oral load.
Based on our results, if we assume a circulating
plasma volume and biomarker distribution of 2.75 L
without clearance, the 99th centile concentrations for
high-sensitivity assays for cTnT (Roche, 14 ng/L), cTnI
(Abbott, 26 ng/L), and cMyC (87 ng/L) can be exceeded
by necrosis of 0.025 g, 0.042 g, and 0.015 g of myocar-
Biomarkers of Necrosis and Amount of MI
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dium, respectively (for calculation, see the online Data
Supplement). The recent guideline by the European So-
ciety of Cardiology defines “rule-out” and  values for
cTn, below which cardiac injury is unlikely (2 ). These
values are close to the LoD concentrations of the high-
sensitivity assays for cTnT and cTnI (5 ng/L and 1.9
ng/L, respectively). Our experiments suggest that 9 mg
and 3 mg of human myocardial necrosis are required to
increase cTnT and cTnI above their LoDs as measured
by high-sensitivity assays, respectively. The correspond-
ing value for cMyC (LoD 0.4 ng/L) is 0.07 mg. Our
experiments simulate a scenario of complete myocardial
necrosis, with subsequent rapid reperfusion and distribu-
tion of the coronary effluent into the systemic circula-
tion. We have also ignored the circulating species of
cTnI, cTnT, and cMyC. Collectively these, and other
unknown factors, make it likely that diagnostic thresh-
olds would in reality require myocardial necrosis more
substantial than we have predicted.
The models of myocardial necrosis we have adopted
are reductionist and convenient but differ markedly from
necrosis of blood-perfused myocardium in vivo. Firstly,
the process of cardiomyocyte necrosis in vivo is more
complex than tissue homogenization. The vast majority
of cTnI, cTnT, and cMyC resides in the crystalline sar-
comere and release from this compartment is slow. The
cause for this slow and incomplete release is uncertain but
is likely related to the quality of reperfusion since the
temporal profile of cTnT differs markedly between alco-
hol septal ablation (low microvascular reflow) and car-
dioplegia (high microvasculature reflow) (15 ). In addi-
tion, myocardial cTnT can be readily released from
myocardium by serum alone, without the need of special-
ist extraction buffers (16 ). Although, we didn’t measure
the cTnI, cTnT, or cMyC remaining in the insoluble
fraction (pellet after centrifugation) following homoge-
nization, it is likely extraction was inefficient since the
concentration of cTnT we observed in human myocar-
dium is lower than those published previously (16, 17 ).
Secondly, the protracted release in vivo provides ample
opportunity for posttranslational modifications, that will
be absent in our models of rapid myocardial homogeni-
zation in calcium-free lysis buffers containing protease
inhibitors. For example, cTnI, cMyC, and cTnT appear
Fig. 1. Graph showing linear regression between number of rat cardiomyocytes and resultant cardiac biomarker concentration as
measured by high-sensitivity assays (hs-cTnI and hs-cTnT) in 400 μL of human serum; cTnI [n = 61, excluding 1 outlier; y = 18.9
(95% CI, 14.7–23.1) × x − 44.6 (95% CI, −128.8 to 39.5); cTnT [n = 62; y = 19 (95% CI, 16.8 –21.2) × x − 24.4 (95% CI, −18.9 to
67.7)] both with spikes into serum from 4 different individuals.
Light gray shading depicts the boundaries of the 95% CIs, with dark gray illustrating their overlap.
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in the circulation as peptides, as well as intact proteins
(15, 18–20). In the case of cMyC, calpain-mediated
cleavage is regulated by phosphorylation events within
the M domain that impede the formation of an
N-terminal peptide (21 ) that is both immunogenic (22 )
and negatively inotropic (23 ). Immunoassays may not
have the same sensitivity for these modified forms of
cTnI, cTnT, and cMyC as they do for the parental un-
modified protein (18, 24 ). If the cleavage event occurs
between the epitopes recognized by the capture and de-
tection antibodies, the immunoassay will become insen-
sitive. Conversely, other posttranslational modifications
are known to enhance the sensitivity of immunoassays.
For example, the sensitivity of assays for cTnI can be
enhanced by oxidation leading to intramolecular disul-
fide formation and also when cTnI is in a binary or ter-
nary complex with cTnC and cTnT (18 ). Furthermore,
the abundance of circulating cTnI, cTnT, and cMyC
peptides changes over time in an individual patient as
well as between patients (15, 18, 20 ). There can also be
marked differences between individual patients in the
proportions of cTnT and cTnI that appear in apo vs
binary and ternary forms (18 ). These complexities were
absent in our experiments where heart tissue was rapidly
homogenized, protease inhibitors prevented protein cleav-
age, opportunities for oxidation were limited and there was
no added calcium to maintain ternary complexes of cTnI/
cTnC/cTnT (18). These details illustrate the simplistic as-
sumptions made in our in vivo extrapolation of volumes of
myocardial necrosis needed to cross diagnostic thresholds.
Nonetheless, they do not invalidate the extreme analytic
sensitivity of the cTnT, cTnT, and cMyC assays and the
microscopic nature of the myocardial necrosis events that
drive clinical decision-making.
Several publications have previously challenged the
thresholds for AMI (acute MI) rule-out as well as the
application of very small  values in clinical practice (6–
8, 25 ). In their analysis, Chenevier-Gobeaux et al. ques-
tioned the cutoff for rule-out at the limit of detection (5
ng/L for cTnT), prompting Peter Kavsak to comment
that there might “be other analytical factors at play that
affected the performance of hs-cTnT” (6, 7 ). Hickman
Fig. 2. Graph showing linear regression between mass of human myocardium and resultant cardiac biomarker concentration as
measured by high-sensitivity assays (hs-cTnI and hs-cTnT) in 400 μL of human serum; n = 36 for each biomarker, each with spikes
into serum from 3 different individuals.
Light gray shading depicts the boundaries of the 95%CIs. Regression equations: cTnI: y=4.3 (95%CI, 3.8–4.7)× x+4.4 (95%CI,−20.1 to 28.8),
cTnT: y=3.9 (95%CI, 3.6–4.3)× x+19 (95%CI, −1.6 to 39.5), cMyC: y=41 (95%CI, 38.0–44.0)× x+91.1 (95%CI, −79.3 to 261.4).
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et al. (8 ) further highlighted the challenges associated
with such narrow decision limits and the use of deltas
when the cTn release might have plateaued—as is the
case with late presentations to the emergency department
and cTn release caused by events other than atheroscle-
rotic plaque instability. Turer et al. have added to the
diagnostic conundrum by describing low-level cTnT re-
lease in the context of ischemia without frank infarction
(25 ). Although newmyocardial scarring on cardiac mag-
netic resonance imaging (cMRI) has been correlated to
cTn measured with a second-generation assay (26 ), this
is limited by the inability of cMRI to detect infarct size
smaller than a gram of myocardium. To our knowledge,
no previous study has directly correlated cardiac damage
at a tissue or cellular level to biomarker concentrations
measured using contemporary high-sensitivity assays.
While there is a significant body of evidence to sug-
gest that di- and tripeptides, derived from dietary protein
can cross the gastrointestinal tract into the portal circu-
lation, the absorption of larger intact polypeptides is con-
troversial (27 ). Based on the closely spaced capture/
detection epitopes used by the cTnI and cTnT assays,
20-mer polypeptides should generate a signal (see Appen-
dix in the online Data Supplement). Given the excep-
tional sensitivity of the high-sensitivity troponin assays,
we hypothesized that we would detect longer cTnI and
cTnT polypeptides in the systemic circulation. This hy-
pothesis was supported by the fact that both of the high-
sensitivity assays for cTnT and cTnI were substantially
more sensitive to cTn in cooked ovine than in human
myocardium. Following a meal of 200 g of ovine myo-
cardium, venous blood was sampled from a healthy hu-
man volunteer at hourly time intervals. Assuming that (a)
the human digestive tract is able to liberate all the cTnT
in ovine myocardium in a manner similar to ultrasonica-
tion, and (b) the entire quantity of liberated cTnT is able
to cross into the systemic circulation, extrapolation of the
calibration curve indicates that serum cTnT should be
increased by 335mg/L. The hs-cTnT assay has sensitivity
to detect 5 ng/L increments in serum troponin. As such,
only 1.5  106% of the dietary cTnT needed to be
released from the myocardium and absorbed into sys-
temic circulation to produce a detectable increase in se-
rum cTnT. Nonetheless, measured cTnT remained con-
sistently below the LoD at all time points after the dietary
load. The same observation was made with cTnI. Even
with the unrealistic assumption of complete liberation of
troponin from the full mass of ingested myocardium, the
Fig. 3. Graph demonstrating available serum biomarker concentration after an oral load of cooked ovinemyocardium at the following
timepoints:0min,15min,1h,2h,3h,4h (missing for cTnI), 22h,28h;allmeasuredvalues remainedbelowtheLoD forhigh-sensitivity
assays (hs-cTnT and hs-cTnI) for the respective biomarkers (cTnT= 5 ng/L, cTnI = 1.9 ng/L; indicated by dotted lines on graph).
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orders of magnitude involved suggest the gastrointestinal
tract is virtually impervious to absorption of intact poly-
peptides of troponin.
In conclusion,we have, for the first time, correlated the
99th centile thresholds of cTn to the approximate mass of
myocardium undergoing complete necrosis. Our experi-
ments have revealed the exquisite sensitivity of the contem-
porary biomarker assays,with necrosis of just 40mgofmyo-
cardium, equivalent to 0.015% of the heart, sufficient to
increase serum concentrations above the 99th centile.
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